These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 8688852)
21. The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Kogure T; Ueno Y; Iwasaki T; Shimosegawa T Cancer Chemother Pharmacol; 2004 Apr; 53(4):296-304. PubMed ID: 14689231 [TBL] [Abstract][Full Text] [Related]
22. [Sensitivity of clonogenic cells of human ascitic ovarian cancer to antitumor agents]. Potapov SL; Korman DB; Shamaev VI; Ershova RB; Makarov OV Eksp Onkol; 1987; 9(4):47-50. PubMed ID: 3678125 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of potentially lethal damage recovery by cisplatin in a brain tumor cell line. Wilkins DE; Heller DP; Raaphorst GP Anticancer Res; 1993; 13(6A):2137-42. PubMed ID: 8297126 [TBL] [Abstract][Full Text] [Related]
24. Direct effects of chemotherapeutic agents on rat prostate tumor clonogenic cells. Geldof AA; Rao BR; de Voogt HJ Anticancer Res; 1986; 6(4):837-40. PubMed ID: 3752961 [TBL] [Abstract][Full Text] [Related]
25. Synergistic interaction of β-galactosyl-pyrrolidinyl diazeniumdiolate with cisplatin against three tumor cells. Deng L; Zhang E; Chen C Arch Pharm Res; 2013 May; 36(5):619-25. PubMed ID: 23494564 [TBL] [Abstract][Full Text] [Related]
26. Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells. Frost P; Abbruzzese JL; Hunt B; Lee D; Ellis M Cancer Res; 1990 Aug; 50(15):4572-7. PubMed ID: 1695122 [TBL] [Abstract][Full Text] [Related]
27. Synergistic effect of peroxiredoxin II antisense on cisplatin-induced cell death. Yo YD; Chung YM; Park JK; Ahn CM; Kim SK; Kim HJ Exp Mol Med; 2002 Sep; 34(4):273-7. PubMed ID: 12515392 [TBL] [Abstract][Full Text] [Related]
28. Enhancement of cisplatin cytotoxicity by terbium in cisplatin-resistant MDA/CH human breast cancer cells. Fuller TL; Canada RG Cancer Chemother Pharmacol; 1999; 44(3):249-52. PubMed ID: 10453727 [TBL] [Abstract][Full Text] [Related]
29. Identification of synergistic combinations of spirogermanium with 5-fluorouracil or cisplatin using a range of human tumour cell lines in vitro. Hill BT; Bellamy AS; Metcalfe S; Hepburn PJ; Masters JR; Whelan RD Invest New Drugs; 1984; 2(1):29-33. PubMed ID: 6540761 [TBL] [Abstract][Full Text] [Related]
30. Effect of feeder cell-released substances on the survival of clonogenic 9L cells after treatment with antimetabolites. Weizsaecker M; Deen DF Cancer Res; 1980 Sep; 40(9):3202-5. PubMed ID: 7000339 [TBL] [Abstract][Full Text] [Related]
31. [The trypanocidal action of fluorouracil on Crithidia oncopelti in the presence of lipid metabolic modifiers]. Sukhareva NN; Titova TS; SUkhanova NV; Syrkin AB Izv Akad Nauk SSSR Biol; 1991; (5):683-8. PubMed ID: 1795072 [TBL] [Abstract][Full Text] [Related]
32. Development and validation of a general approach to predict and quantify the synergism of anti-cancer drugs using experimental design and artificial neural networks. Pivetta T; Isaia F; Trudu F; Pani A; Manca M; Perra D; Amato F; Havel J Talanta; 2013 Oct; 115():84-93. PubMed ID: 24054565 [TBL] [Abstract][Full Text] [Related]
33. Cytotoxicity of dimethyl sulfoxide and antineoplastic combinations against human tumors. Pommier RF; Woltering EA; Milo G; Fletcher WS Am J Surg; 1988 May; 155(5):672-6. PubMed ID: 3369622 [TBL] [Abstract][Full Text] [Related]
34. [Growth of tumour-cell colonies from human solid tumours (author's transl)]. Schlag P; Wolfrum J; Vergani G; Schreml W; Herfarth C Dtsch Med Wochenschr; 1982 Aug; 107(31-32):1173-7. PubMed ID: 6179731 [TBL] [Abstract][Full Text] [Related]
35. Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines. Zaffaroni N; Orlandi L; Gornati D; De Marco C; Vaglini M; Silvestrini R Eur J Cancer; 1996 Sep; 32A(10):1766-73. PubMed ID: 8983288 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of methionine uptake by cis-diamminedichloroplatinum (II) in experimental brain tumors. Mineura K; Sasajima T; Sasajima H; Kowada M Int J Cancer; 1996 Sep; 67(5):681-3. PubMed ID: 8782658 [TBL] [Abstract][Full Text] [Related]
37. Synergistic cytotoxicity between dimethyl sulfoxide and antineoplastic agents against ovarian cancer in vitro. Pommier RF; Woltering EA; Milo G; Fletcher WS Am J Obstet Gynecol; 1988 Oct; 159(4):848-52. PubMed ID: 3177534 [TBL] [Abstract][Full Text] [Related]
38. Transferrin-cisplatin specifically deliver cisplatin to HepG2 cells in vitro and enhance cisplatin cytotoxicity. Luo LZ; Jin HW; Huang HQ J Proteomics; 2012 Dec; 77():237-50. PubMed ID: 22986151 [TBL] [Abstract][Full Text] [Related]
39. An interaction of cisplatin and radiation in two rat yolk sac tumour cell lines with different radiosensitivities in vitro. Nakamoto S; Mitsuhashi N; Takahashi T; Sakurai H; Niibe H Int J Radiat Biol; 1996 Dec; 70(6):747-53. PubMed ID: 8980672 [TBL] [Abstract][Full Text] [Related]
40. In vitro FTIR microspectroscopy analysis of primary oral squamous carcinoma cells treated with cisplatin and 5-fluorouracil: a new spectroscopic approach for studying the drug-cell interaction. Giorgini E; Sabbatini S; Rocchetti R; Notarstefano V; Rubini C; Conti C; Orilisi G; Mitri E; Bedolla DE; Vaccari L Analyst; 2018 Jul; 143(14):3317-3326. PubMed ID: 29931010 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]